Duotol Ab

Scandinavian Biopharma Holding Ab

Vitec Aktiebolag

Pharmacia Aktiebolag

Cardiovax, LLC

Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.

Syntello Vaccine Development Kb

Scandinavian Biopharma Holding Ab, C/o Etvax Ab

Jan Holmgren

Cecil Czerkinsky

Ann-Mari Svennerholm

Nils Carlin

Joshua Tobias

Joaquin Sanches Castillo

Jan Nilsson

Lars Rymo

Stig Jeansson

Peter Horal

Anders Vahlne

Bo Svennerholm

Peter Lind

Michael Lebens

Leif G Lindholm

Göran K Hansson

An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivatedcells expressing an ETEC colonization factor antigen and dmLT protein adjuvant, wherein the vaccine preferably comprises less than 10cells per unit dose.

Vaccine for protection against ETEC-induced diarrhea comprising dmLT

A vaccine against cholera and/or ETEC is provided, comprising aO1 cell, characterized in that said cell comprises O1 antigens of both Ogawa and lnaba serotypes. Genetically modifiedO1 cells for use in such vaccines, DNA-constructs for the modification, uses for the vaccine and methods of making a vaccine are also provided.

[object Object]

A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems.

Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis

An immunological tolerance-inducing agent comprising a mucosa-binding molecule linked to a specific tolerogen is disclosed. Further, a method of inducing immunological tolerance in an individual against a specific antigen, including hapten, which causes an unwanted immune response in said individual comprising administration by a mucosal route of an immunologically effective amount of an immunological tolerance-inducing agent of the invention to said individual, is described.

Immunological tolerance-inducing agent

An agent comprising a mucosa-binding molecule linked to a specific microbial antigen is disclosed. Further, a method of inducing immunological tolerance in an individual against a specific microbial antigen, including hapten, which causes an unwanted immune response in said individual, comprising administration by a mucosal route of an immunologically effective amount of an immunological tolerance-inducing agent of the invention to said individual, is described.

Disclosed herein are procedures whereby with the aid of recombinant DNA methods, the expression of the binding subunit protein of cholera toxin (CTB) or derivatives thereof including hybrid gene fusion proteins to CTB has been brought under the control of a foreign (non-cholera toxin) promoter and/or the CTB protein or its derivatives being synthesized with a foreign rather than the natural leader peptide to facilitate translocation across cell membranes.

Recombinant systems for expression of the cholera B-sub-unit with the

Recombinant systems for expression of cholera B-subunit with the aid of

A monoclonal antibody that reacts with the CA-242 antigen is provided. The antibody can be obtained by culturing the hybridoma cell line C242:II with the ECACC identification number 90012601, or an artificial or spontaneous mutant thereof. Cell lines producing the antibody are also provided. The antibody is useful for therapeutic and diagnostic purposes.

Tumor antigen specific antibody

Peptides corresponding to regions of the human immunodeficiency virus protein gp-120 are provided for eliciting T-cell activation.

Peptides for use in induction of T cell activation against HIV-1

Growing community of inventors

Vastra Frolunda, Sweden

Jan Holmgren